Following the review of of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the strength of budesonide nasal spray be updated to reflect the available product strengths. The Committee also recommended the listing description be changed from 'per dose' to 'per actuation' as the administered dose may comprise more than one actuation (spray).